XERS Xeris Biopharma Holdings, Inc.
Healthcare$6.26+1.13%ClosedMarket Cap: $1.08B
As of 2026-05-26
Valuation
P/E (TTM)
1827.02
PEG
18.09
P/B
81.13
P/S
3.39
EV/EBITDA
22.13
DCF Value
$-63.37
FCF Yield
4.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.6%
Operating Margin
11.4%
Net Margin
3.8%
ROE
735.0%
ROA
3.1%
ROIC
12.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $83.1M | 84.0% | $7.9M | $2.2M | $— | — |
| Q4 null | $85.8M | 77.8% | $16.8M | $11.1M | $— | — |
| FY null | $291.8M | 81.7% | $24.9M | $554.0K | $— | — |
| Q3 null | $74.4M | 85.2% | $6.7M | $621.0K | $— | — |
| Q2 null | $71.5M | 79.6% | $4.5M | $-1.9M | $— | — |
| Q1 null | $60.1M | 85.5% | $-3.1M | $-9.2M | $— | — |
| Q4 null | $60.1M | 84.2% | $1.7M | $-5.1M | $— | — |
| FY null | $203.1M | 81.9% | $-33.6M | $-54.8M | $— | — |
| Q3 null | $54.3M | 75.0% | $-12.9M | $-15.7M | $— | — |
| Q2 null | $48.1M | 78.2% | $-8.2M | $-15.0M | $— | — |
| Q1 null | $40.6M | 85.3% | $-14.2M | $-19.0M | $— | — |
| Q4 2023 | $44.4M | 76.8% | $-9.8M | $-13.4M | $-0.10 | — |